Table 1.

Adverse events (FAS).

Preferred term	IVA monotherapy group (n = 24)	IVA + SL combination therapy group (n = 25)
Ocular local adverse events, n (%)	4 (16.7)	2 (8.0)
Cataract	2 (8.3)	1 (4.0)
Dry eye	1 (4.2)	0
Normal tension glaucoma	1 (4.2)	0
Macular hole	0	1 (4.0)
Non-ocular adverse events, n (%)	4 (16.7)	3 (12.0)
Fracture	1 (4.2)	1 (4.0)
Pneumonia	1 (4.2)	0
Colon cancer	1 (4.2)	0
Renal failure	1 (4.2)	0
Myocardial infarction	0	1 (4.0)
Sudden deafness	0	1 (4.0)

FAS full analysis set; IVA intravitreal injection of aflibercept; SL subthreshold laser.